Johannes Gutenberg-Universität Mainz
- 6131/39-0
Walsh, C. L.; Tafforeau, P.; Wagner, W. L. et al.
Imaging intact human organs with local resolution of cellular structures using hierarchical phase-contrast tomographyNATURE METHODS. Bd. 18. H. 12. 2021 S. 1532-+
Eltokhi, Ahmed; Gonzalez-Lozano, Miguel A.; Oettl, Lars-Lennart et al.
Imbalanced post- and extrasynaptic SHANK2A functions during development affect social behavior in SHANK2-mediated neuropsychiatric disordersMOLECULAR PSYCHIATRY. Bd. 26. H. 11. 2021 S. 6482-6504
Eltokhi, Ahmed; Gonzalez-Lozano, Miguel A.; Oettl, Lars-Lennart et al.
Imbalanced post- and extrasynaptic SHANK2A functions during development affect social behavior in SHANK2-mediated neuropsychiatric disorders (May, 10.1038/s41380-021-01140-y, 2021)MOLECULAR PSYCHIATRY. Bd. 26. H. 11. 2021 S. 6505-6505
Ducreux, Michel; Zhu, Andrew X.; Cheng, Ann-Lii et al.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Zhu, Andrew X.; Finn, Richard; Ducreux, Michel et al.
IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY. Bd. 74. 2021 S. 646A-647A
Breder, Valeriy Vladimirovich; Vogel, Arndt; Merle, Philippe et al.
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)SWISS MEDICAL WEEKLY. Bd. 151. 2021 S. 25-26
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).CANCER RESEARCH. Bd. 81. H. 13. 2021
Finn, Richard S.; Qin Shukui, ?; Ikeda, Masafumi et al.
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Galle, P.; Finn, R. S.; Qin, S. et al.
IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 34-34